DermTech Return on Equity

DermTech (DMTK) currently reports a ROE of -224.1%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore DermTech's ROE history and peer comparisons.

DermTech's ROE of -224.1% is lower than the Healthcare sector average of -100.59%. That is roughly 122.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but DermTech's current -224.1% should be judged against Healthcare norms (sector average: -100.59%) and against DMTK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -224.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for DermTech, and consider following DMTK for alerts when major investors trade the stock.

DermTech is classified in the Healthcare sector. On ROE, it currently shows -224.1% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DMTK with unrelated industries.